Elevation Oncology Inc
NASDAQ:ELEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Balnibarbi Co Ltd
TSE:3418
|
JP |
|
Mobico Group PLC
LSE:MCG
|
UK |
|
A
|
A-Smart Holdings Ltd
SGX:BQC
|
SG |
|
Z
|
Zhi Sheng Group Holdings Ltd
HKEX:8370
|
CN |
|
Amlogic Shanghai Co Ltd
SSE:688099
|
CN |
|
P
|
Pearson PLC
NYSE:PSO
|
UK |
|
S
|
Safeture AB
STO:SFTR
|
SE |
|
S
|
Sling Group Holdings Ltd
HKEX:8285
|
HK |
|
Jubilant Ingrevia Ltd
NSE:JUBLINGREA
|
IN |
Elevation Oncology Inc
EPS (Diluted)
Elevation Oncology Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elevation Oncology Inc
NASDAQ:ELEV
|
EPS (Diluted)
$0
|
CAGR 3-Years
33%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Elevation Oncology Inc
Glance View
Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.
See Also
What is Elevation Oncology Inc's EPS (Diluted)?
EPS (Diluted)
-0.8
USD
Based on the financial report for Dec 31, 2024, Elevation Oncology Inc's EPS (Diluted) amounts to -0.8 USD.
What is Elevation Oncology Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-25%
Over the last year, the EPS (Diluted) growth was 42%. The average annual EPS (Diluted) growth rates for Elevation Oncology Inc have been 33% over the past three years , -25% over the past five years .
